Denial, good pick up....that's a high percentage...a higher percentage of satisfied patients has a direct co-relation on the success of a drug not withstanding AE's.
Another positive that none of you have picked up or at least posted, is the trial size...yes even I was thinking the Phase three would be around 500 patients...may be as high as 600 and then we all read it's (combined) going to be around 1100...
Guys, the usual range is 1000 - 3000...we are at the LOW END...this is also good news...
Reference: https://www.sciencedirect.com/science/article/pii/S2452302X1600036X
Valuation and Targets, page-348
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 17420 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |